Locations: Addenbrooke's Hospital, The Beatson West of Scotland Cancer Centre, Royal Marsden Hospital, University College London Hospital, Nottingham City Hospital, Queen Elizabeth Hospital, Weston Park Hospital, The Christie

Full title: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study

Age: 18+

Phase: 3

This study aims to find out whether giving patients adjuvant imatinib for a total of 5 years may prevent some of the GISTs recurring compared to patients who receive adjuvant imatinib for 3 years. GIST patients who have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated to receive imatinib for 2 more years (Arm A) or to stop imatinib (Arm B). Participants are required to have histologically verified GIST with a high risk of GIST recurrence despite removal of all macroscopic GIST tissue at surgery and 3 years of adjuvant imatinib.

To find out more about this trial and whether you could take part, talk to your clinical team.